BioCity Biopharma’s selective endothelin receptor type A (ETA) antagonist has reduced excess proteins in the urine of patients with diabetic kidney disease (DKD), hitting a primary endpoint of a ...

At the American Society of Nephrology (ASN) Kidney Week 2023 congress ... an endothelin A (ETA) receptor antagonist, on levels of albumin in the urine (albuminuria), a surrogate marker for ...

Idorsia Ltd (SIX: IDIA) today announced that the exclusivity agreement signed in November 2024 with an undisclosed party for the global rights to aprocitentan has concluded without the party signing ...